Dna-Coated Carbon Adsorbents Experimental Assessment and Results Op Severe Psoriasis Treatment

Abstract

Newly developed combined adsorbents, containing from 1 to 8 mg of thymic DNA per 1 g of the granulated or the fibrous carbonic matrix, demonstrated good biocompatibility and selectivity for DNA- and DNP-binding substances. In a group of 14 patients with severe psoriasis (uncontrol trial) a single hemoperfusion procedure through DNA-coated granulated synthetic carbons (perfusion volume was 2.5-3.1 L, sorbent quantity was 30 g) resulted in complete remission in 6 patients and in substantial improvement of clinical status in 6 other patients. A positive effect was observed in 4 patients during 7-11 months; in 8 patients it is being observed for more than 29-33 months. The double-blind tests in the group of patients subjected to hemoperfusion through the DNA-coated charcoal (27 people) and uncoated charcoal (9 people) showed the full-scale remission in 55.5% and 11.2% respectively. The authors believe that the DNA-coated activated carbons can be an effective therapeutic procedure for treatment of numerous immuno-dependent diseases and states associated with disorders in the kinetics of cell division.

Hemoperfusion Through Dna-Coated and Uncoated Synthetic Activated Charcoals as an Additive to the Bronchial Asthma Traditional Treatment

“…A number of studies showed that the development of endogenous bronchial asthma is accompanied by autoimmune component (4),microbe's allergy (S),impairment of DNA reparation in lymphocytes ( 6 ) , and increased level of DNA and of anti-DNA and to try a new type of DNA-containing henioimmunoadsorbents (8) in the treatment of patients with endogenous bronchial asthma. A number of studies showed that the development of endogenous bronchial asthma is accompanied by autoimmune component (4),microbe's allergy (S),impairment of DNA reparation in lymphocytes ( 6 ) , and increased level of DNA and of anti-DNA and to try a new type of DNA-containing henioimmunoadsorbents (8) in the treatment of patients with endogenous bronchial asthma.…”